Physician profile
Asim S Khan
NPI 1073557641
$1,166,420.97
in general payments reported to CMS, 2019-2025
25 companies · $174K in 2025
The $174K reported for 2025 was more than what 99% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $246K · 2020: $67K · 2021: $109K · 2022: $183K · 2023: $227K · 2024: $161K · 2025: $174K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $399K · Travel and Lodging: $95K · Honoraria: $46K · Consulting Fee: $16K · Food and Beverage: $7,609 · Gift: $40.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $398,896.25 |
| Travel and Lodging | $94,722.58 |
| Honoraria | $45,585.00 |
| Consulting Fee | $15,500.00 |
| Food and Beverage | $7,608.53 |
| Gift | $40.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $232,329.17 | 2019-2025 | Bimzelx, Cimzia |
| Amgen INC. | $168,960.18 | 2020-2025 | Krystexxa, Otezla, Otezla |
| Astrazeneca Pharmaceuticals Lp | $159,964.46 | 2022-2025 | Saphnelo |
| Horizon Therapeutics Plc | $124,595.54 | 2019-2023 | Krystexxa |
| Mallinckrodt Hospital Products INC. | $111,344.75 | 2020-2025 | Acthar |
| Lilly USA, LLC | $101,141.56 | 2019-2025 | Taltz |
| Novartis Pharmaceuticals Corporation | $94,076.36 | 2019-2022 | |
| Celgene Corporation | $42,447.45 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $40,628.62 | 2019-2021 | |
| Abbvie INC. | $24,357.52 | 2019-2025 | |
| Mallinckrodt Enterprises LLC | $23,431.65 | 2019 | |
| Janssen Biotech, INC. | $16,957.29 | 2019-2024 | Tremfya |
| Pfizer INC. | $15,021.81 | 2019-2024 | |
| Genentech USA, INC. | $5,873.13 | 2019-2023 | Actemra |
| Ferring Pharmaceuticals INC. | $5,038.07 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $39.04 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $37.35 | 2022-2023 | |
| Genzyme Corporation | $36.00 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.38 | 2019 | |
| Fidia Pharma USA INC. | $23.66 | 2019 | |
| Kiniksa Pharmaceuticals, Ltd. | $21.61 | 2021 | |
| Sanofi-Aventis U.S. LLC | $19.76 | 2019 | |
| Daiichi Sankyo INC. | $17.45 | 2019 | |
| Depuy Synthes Sales INC. | $14.03 | 2019 | |
| Merck Sharp & Dohme LLC | $12.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asim Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.